12.01.2013 Views

EANM Drug Development Committee – Activity Report

EANM Drug Development Committee – Activity Report

EANM Drug Development Committee – Activity Report

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>EANM</strong> TG&C ACTIVITY MATRIX<br />

FOR THE PERIOD 11/2008 – 10/2009<br />

<strong>EANM</strong> <strong>Drug</strong> <strong>Development</strong> <strong>Committee</strong> – <strong>Activity</strong> <strong>Report</strong><br />

COMMITTEE COMPOSITION<br />

Position Name Responsibility<br />

Chair Christer Halldin (Stockholm, SE) To complete the assigned objectives and<br />

communication with the <strong>EANM</strong> Exectutive<br />

<strong>Committee</strong> through the TG&C Coordinator;<br />

CME and congress sessions<br />

Vice Chair Piero Salvadori (Pisa, IT) To assist the Chair as called upon, to act as<br />

Secretary of the <strong>Committee</strong> etc..<br />

Member Jean-Robert Deverre (Orsay, FR) Web page<br />

Member Bengt Långström (Uppsala, SE)<br />

Member Alfons Verbruggen (Leuven, BE)<br />

Preparing and updating guidelines<br />

Preparing and updating guidelines<br />

Member Denis Guilloteau (Tours, FR) Relations with the interest group and national<br />

advisers; relations with DIMI.<br />

Member Heinz Coenen (Juelich, DE) Preparing and updating guidelines<br />

Co-opted<br />

Member –<br />

when given<br />

IAEA Observer: Kishor Solanki<br />

Ludger Dinkelborg (Berlin, DE)<br />

<strong>EANM</strong> Executive Secretariat<br />

Hollandstrasse 14/Mezzanine, A - 1020 Vienna, Austria<br />

Tel: +43-1-2128030, Fax: +43-1-21280309<br />

e-mail: office@eanm.org, http://www.eanm.org


<strong>EANM</strong> TG&C ACTIVITY MATRIX<br />

FOR THE PERIOD 11/2008 – 10/2009<br />

ACTIVITIES DURING THE PERIOD FROM <strong>EANM</strong>’08 MUNICH TO <strong>EANM</strong>’09 BARCELONA<br />

Guidelines:<br />

� Guideline on “Regulations for Radiopharmaceuticals in Early Phase Clinical Studies in the EU”<br />

(published November 2008)<br />

� New Guideline planned on “Principles on Using Imaging on the <strong>Development</strong> of New <strong>Drug</strong>s for the<br />

CNS”<br />

CME / Symposia / Debates to be delivered during <strong>EANM</strong>’09 in Barcelona:<br />

� <strong>EANM</strong>’09 CME Session together with the Radiopharmacy <strong>Committee</strong> on “State of the Art Radio-<br />

Pharmaceutical Production”<br />

� <strong>EANM</strong>’09 CME Session together with the Neuroimaging <strong>Committee</strong> on “Imaging targets<br />

Dementia”<br />

� <strong>EANM</strong>’09 Symposia on “Imaging oncology in drug development” C.Halldin/P.Salvadori<br />

Liaison with related societies (name of society, abbreviation, website):<br />

� DIMI (Diagnostics in Molecular Imaging) EU Center of Excellence program<br />

� ESRR (European Society of Radiopharmacy and Radiopharmaceuticals<br />

Contributions to congresses of related societies / Research activities with related societies:<br />

� A combined course within the DIMI was given in Tours, Nov 3-7, 2008<br />

Other activities:<br />

� Work towards harmonizing regulatory requirements for imaging tracers between the US and the<br />

EU” together with Radiopharmacy C. To support the development of an European eIND similar to<br />

FDA. Give comments to appropriate EMEA drafts.<br />

� Participating in a Roundtable at “Imaging Biomarkers Roundtable, USA, 2009.<br />

<strong>EANM</strong> Executive Secretariat<br />

Hollandstrasse 14/Mezzanine, A - 1020 Vienna, Austria<br />

Tel: +43-1-2128030, Fax: +43-1-21280309<br />

e-mail: office@eanm.org, http://www.eanm.org

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!